SL
KLRS

Siren LLC’s Kalaris Therapeutics KLRS Stock Holding History

Siren LLC’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Hold
435,798
– – 0.04% 105
2026
Q1 		$2.51M Hold
435,798
– – 0.07% 87
2025
Q4 		$3.68M Buy
435,798
+117,534
+37% +$752K 0.11% 89
2025
Q3 		$1.84M Buy
318,264
+35,678
+13% +$118K 0.07% 91
2025
Q2 		$755K Hold
282,586
– – 0.04% 99
2025
Q1 		$2.27M Sell
282,586
-4,247
-1% -$41.6K 0.13% 81
2024
Q4 		$2.77M Hold
286,833
– – 0.12% 83
2024
Q3 		$5.33M Buy
+286,833
New +$5.02M 0.27% 66

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Siren LLC's KLRS Position: Q2 2026 in Review

Siren LLC held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 435,798 shares worth $1.77M. The position accounts for 0.04% of the portfolio, ranked #105.

Siren LLC first reported a position in KLRS in Q3 2024 and has held it in 8 quarters since. The position peaked at $5.33M in Q3 2024. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Siren LLC held 435,798 shares of Kalaris Therapeutics worth $1.77M as of Q2 2026.
  • Siren LLC left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up 0.04% of Siren LLC's portfolio in Q2 2026, its #105 holding.
  • Siren LLC first reported a position in Kalaris Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Siren LLC's Kalaris Therapeutics position peaked at $5.33M in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.